{"id":"W3196898846","doi":"10.1016/s2152-2650(21)01833-4","title":"MPN-332: Clinical Benefit of Pelabresib (Cpi-0610) in Combination with Ruxolitinib in JAK Inhibitor Treatment-Naïve Myelofibrosis Patients: Interim Efficacy Subgroup Analysis from Arm 3 of the MANIFEST Phase 2 Study","year":2021,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Ruxolitinib; Medicine; Context (archaeology); Myelofibrosis; Internal medicine; Clinical endpoint; Gastroenterology; Phases of clinical research; Clinical trial; Bone marrow; Biology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001748794,0.0006625046,0.003020833,0.0006030577,0.00009148282,0.00005488793,0.0007249101,0.0006415008,0.0002893678],"category_scores_gemma":[0.00317224,0.0004833938,0.001207221,0.00344268,0.0009649573,0.0002192255,0.0006000019,0.0006373088,0.00003259557],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.01332741,"about_ca_system_score_gemma":0.009127766,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005883147,"about_ca_topic_score_gemma":0.005608736,"domain_scores_codex":[0.9897597,0.001518121,0.004711632,0.00164655,0.001526921,0.0008370884],"domain_scores_gemma":[0.9902384,0.00480224,0.001257536,0.002305929,0.0009104603,0.0004854022],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.009443871,0.03745395,0.8127077,0.0001138953,0.002019357,0.0006050025,0.001187135,0.00004675404,0.0001911272,0.00008839879,0.00006380063,0.136079],"study_design_scores_gemma":[0.1533251,0.008799978,0.8286257,0.0007285261,0.001650219,0.00001748422,0.001280693,0.002797857,0.002229634,0.00007634793,0.0001160142,0.0003524397],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.996309,0.0002303022,0.00001207648,0.0001908779,0.0003787324,0.002110026,0.0002220972,0.0000458397,0.0005010244],"genre_scores_gemma":[0.9980049,0.0002092875,0.000346727,0.0001629279,0.0002559221,0.0001211168,0.0005423106,0.00009364633,0.0002631758],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1438812,"threshold_uncertainty_score":0.9997618,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04502401486873477,"score_gpt":0.3788864568032972,"score_spread":0.3338624419345625,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}